Related Experiment Video

Updated: Sep 20, 2026

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice
15:45

Cardiac Stress Test Induced by Dobutamine and Monitored by Cardiac Catheterization in Mice

Published on: February 10, 2013

Patients with early diabetic heart disease demonstrate a normal myocardial response to dobutamine

Zhi You Fang1, Ofelia Najos-Valencia, Rodel Leano

  • 1University of Queensland, Brisbane, Australia.

Journal of the American College of Cardiology
|August 9, 2003
PubMed

Insights

Diabetic cardiomyopathy shows subtle left ventricular (LV) dysfunction, but the response to stress is normal. This suggests ischemia from small-vessel disease is unlikely in early diabetic heart muscle disease.

Area of Science:

  • Cardiology
  • Diabetology
  • Myocardial Physiology

Background:

  • Diabetic cardiomyopathy is a recognized clinical and experimental condition.
  • The underlying causes of diabetic cardiomyopathy remain incompletely understood.
  • Investigating early signs of cardiac dysfunction in diabetes is crucial.

Purpose of the Study:

  • To assess regional left ventricular (LV) response to stress using quantitative markers.
  • To determine if diabetic cardiomyopathy is associated with myocardial ischemia.
  • To investigate subtle LV dysfunction in diabetic patients without overt cardiac disease.

Main Methods:

  • Studied 41 diabetic patients and 41 controls with normal resting LV function.
  • Utilized dobutamine echocardiography to assess myocardial velocities.
  • Measured peak myocardial systolic velocity (Sm) and early diastolic velocity (Em) at rest and during stress.

Main Results:

  • Diabetic patients exhibited significantly lower baseline Sm compared to controls.
  • Early diastolic velocity (Em) was significantly lower in diabetic patients across all stress levels.
  • Both groups showed similar absolute and relative increases in Sm and Em from rest to peak stress.

Conclusions:

  • Subtle left ventricular (LV) dysfunction is present in diabetic patients without apparent cardiac disease.
  • The preserved response to dobutamine stress suggests ischemia is not a primary driver of early diabetic heart muscle disease.
  • Further research is needed to elucidate the mechanisms of diabetic cardiomyopathy.
Abstract

More Related Videos

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...